SCHEMBL1421375

SCHEMBL1421375

O=c1c(O)c(-c2cccc3occc23)oc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMUR2 Q9GZQ4 4/20 0.62
KDM4E B2RXH2 11/20 0.59
MEN1 O00255 10/20 0.59
KMT2A Q03164 10/20 0.59
CYP3A4 P08684 9/20 0.59
TP53 P04637 6/20 0.59
MAPK1 P28482 5/20 0.59
ALOX15 P16050 4/20 0.59
LMNA P02545 3/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
ABCB1 P08183 1/20 0.59
CALM1 P0DP23 1/20 0.59
AR P10275 1/20 0.59
PKM P14618 1/20 0.59
CYP1B1 Q16678 1/20 0.59
CA9 Q16790 1/20 0.59
HSD17B10 Q99714 7/20 0.58
ALDH1A1 P00352 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773152 0.83 NMUR2 (0.68) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL471860 0.80 NMUR2 (0.68) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL31675811 0.80 NMUR2 (0.71) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL290080 0.80 NMUR2 (0.71) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL16586869 0.77 NMUR2 (0.68) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL15676117 0.77 NMUR2 (0.68) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL6095363 0.77 NTRK1 (0.63) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL3062193 0.76 KDM4E (0.72) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL2746872 0.76 MEN1 (0.90) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL9080388 0.76 MEN1 (0.62) NMUR2KDM4EMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 US disclosed
EP-2297127-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AxoGlia Therapeutics S.A. (LU) 2011-03-23 EP disclosed
WO-2009130253-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS S.A. (LU) 2009-10-29 WO disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA NMUR2 909/4885KDM4E 2608/4885MEN1 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.